Disclosed is the use of pirfenidone in the manufacture of a medicament for treating a patient in need of pirfenidone therapy, wherein the treatment comprises avoiding or discontinuing concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2) to avoid reduced exposure to pirfenidone.